VUMERITY

Peak

diroximel fumarate

NDAORALCAPSULE, DELAYED RELEASE
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8

Clinical Trials (5)

NCT05767736N/AActive Not Recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Started Jun 2024
10,500 enrolled
Multiple Sclerosis
NCT05658497N/ARecruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Started Oct 2023
908 enrolled
Multiple Sclerosis
NCT05798520Phase 2Completed

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Started Jul 2023
127 enrolled
Relapsing Forms of Multiple Sclerosis
NCT04948606N/ATerminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel

Started Dec 2021
64 enrolled
Relapsing Forms of MS
NCT05127564Phase 1Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants

Started Dec 2021
32 enrolled
Healthy Volunteers

Loss of Exclusivity

LOE Date
Oct 29, 2033
93 months away
Patent Expiry
Oct 29, 2033

Patent Records (3)

Patent #ExpiryTypeUse Code
10080733
Sep 20, 2033
SubstanceProduct
U-1384
9090558
Sep 20, 2033
U-1384
8669281
Oct 29, 2033
SubstanceProduct